Cost-Effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy as first-line maintenance for patients with advanced ovarian cancer: a analysis from a Chinese healthcare perspective.
Objective: The PAOLA-1 trial demonstrated that olaparib plus bevacizumab (OB) significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to bevacizumab monotherapy (BM) as first-line maintenance therapy for patients with advanced ovarian cancer (AOC) who had homologou...
| Publicado en: | DARU: Journal of Pharmaceutical Sciences Vol. 34; no. 2; pp. 1 - 14 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Springer Nature
7/22/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |